Some people who liked of information that are in this blog #@ Algumas pessoas que gostaram de informações que estão neste blog – Professor Dr. Emery Neal Brown Dr. Fred Warren McLafferty Professor Dr. Jeroen J. Bax Professor Dr. Domingo Marcolino Braile Professor Dr. Denis Noble Professor Dr. James D. Griffin Professor Dr. Jeffrey Michael Karp Professora Dra. Eliane Carneiro Gomes Dr. Howard Young @ Researchers demonstrate new path to reliable quantum computation @ ´´It combined the high speed of electronics with the ability to be programmed for many complex problems. It could add or subtract 5000 times a second, a thousand times faster than any other machine. Built under the direction of John Mauchly and J. Presper Eckert at the University of Pennsylvania, ENIAC’s development and construction lasted from 1943 to full operation at the end of 1945.´´ @ OTHER VERY IMPORTANT INFORMATION OF THE WORLD LIKE WEBSITES, LINKS AND IMAGES #time #tempo #blog #post #data #reading #typing #times

Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!

  • – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – ´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World

Pathol Res Pract. 2012 Jul 15;208(7):377-81. doi: 10.1016/j.prp.2012.04.006. Epub 2012 Jun 8.

The influence of physical activity in the progression of experimental lung cancer in mice

Renato Batista Paceli 1Rodrigo Nunes CalCarlos Henrique Ferreira dos SantosJosé Antonio CordeiroCassiano Merussi NeivaKazuo Kawano NagaminePatrícia Maluf Cury


GRUPO_AF1 – GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 1 – GROUP AFAN1 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO_AF2 – GROUP AFA2 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 2 – GROUP AFAN 2 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

Slides – mestrado – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto



Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto


Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.

Professor Dr. Emery Neal Brown

1 – Dr. Fred Warren McLafferty 

2 – Professor Dr. Jeroen J. Bax

3 – Professor Dr. Domingo Marcolino Braile

4 – Professor Dr. Denis Noble

5 – Professor Dr. James D. Griffin

6 – Professor Dr. Jeffrey Michael Karp

7 – Professora Dra. Eliane Carneiro Gomes

8. Dr. Howard Young

Dr. Emery N. Brow


Professor Dr. Jeffrey Michael Karp

Bioengineer, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women’s Hospital
Department of Medicine
75 Francis Street
Boston, MA 02115

Research Location: 65 Lansdowne Street

Phone: (617) 817-9174
Research Email:
Massachusetts Institute of Technology (with Bob Langer), 2004-2007, Postdoctoral Fellow
University of Toronto, 2004, Ph.D.
McGill University , 1999, B.Eng.

2011 Society For Biomaterials Young Investigator Award
2009 Gecko Adhesive Technology selected by Popular Mechanics Top 10 Next Medical Breakthrough
2008 TR35 – Recognized as one of the world’s top innovators under age 35, Technology Review-MIT
2010 Coulter Foundation Translational Young Investigator Award
2013 Elected to the American Institute for Medical and Biological Engineering’s College of Fellows
2011 Champion in Healthcare, “Innovator” by Boston Business Journal
2010 HST McMahon Mentoring award– top mentor among all faculty who mentor Harvard/MIT students

Link to PubMed:
View Karp’s Publications in PubMed.

Publications (Pulled from Harvard Catalyst Profiles):
1. Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Transl Med. 2019 Feb 08.

2. Fries CA, Lawson SD, Wang LC, Slaughter KV, Vemula PK, Dhayani A, Joshi N, Karp JM, Rickard RF, Gorantla VS, Davis MR. Graft-implanted, enzyme responsive, tacrolimus-eluting hydrogel enables long-term survival of orthotopic porcine limb vascularized composite allografts: A proof of concept study. PLoS One. 2019; 14(1):e0210914.

3. Lam C, Meinert E, Alturkistani A, Carter AR, Karp J, Yang A, Brindley D, Cui Z. Decision Support Tools for Regenerative Medicine: Systematic Review. J Med Internet Res. 2018 Dec 19; 20(12):e12448.

4. Ng KS, Smith JA, McAteer MP, Mead BE, Ware J, Jackson FO, Carter A, Ferreira L, Bure K, Rowley JA, Reeve B, Brindley DA, Karp JM. Bioprocess decision support tool for scalable manufacture of extracellular vesicles. Biotechnol Bioeng. 2019 Feb; 116(2):307-319.

5. Lee Y, Deelman TE, Chen K, Lin DSY, Tavakkoli A, Karp JM. Therapeutic luminal coating of the intestine. Nat Mater. 2018 Sep; 17(9):834-842.

6. Mead BE, Ordovas-Montanes J, Braun AP, Levy LE, Bhargava P, Szucs MJ, Ammendolia DA, MacMullan MA, Yin X, Hughes TK, Wadsworth MH, Ahmad R, Rakoff-Nahoum S, Carr SA, Langer R, Collins JJ, Shalek AK, Karp JM. Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types. BMC Biol. 2018 06 05; 16(1):62.

7. Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter KV, Sherman NE, Amirault J, Wang Y, Riegel L, He X, Rui TS, Valic M, Vemula PK, Miranda OR, Levy O, Gravallese EM, Aliprantis AO, Ermann J, Karp JM. Author Correction: Towards an arthritis flare-responsive drug delivery system. Nat Commun. 2018 05 11; 9(1):1954.

8. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018 04 12; 9(1):1410.

9. Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter KV, Sherman NE, Amirault J, Wang Y, Riegel L, He X, Rui TS, Valic M, Vemula PK, Miranda OR, Levy O, Gravallese EM, Aliprantis AO, Ermann J, Karp JM. Towards an arthritis flare-responsive drug delivery system. Nat Commun. 2018 04 03; 9(1):1275.

10. Mitsouras D, Tao M, de Vries MR, Trocha K, Miranda OR, Vemula PK, Ding K, Imanzadeh A, Schoen FJ, Karp JM, Ozaki CK, Rybicki FJ. Early animal model evaluation of an implantable contrast agent to enhance magnetic resonance imaging of arterial bypass vein grafts. Acta Radiol. 2018 Sep; 59(9):1074-1081.

show all

Jeffrey Karp

From Wikipedia, the free encyclopedia Jump to navigationJump to search

Jeff Karp
Jeffrey Karp
ResidenceUnited States
Alma materMcGill University, University of Toronto, Massachusetts Institute of Technology
Scientific career
FieldsBiomedical engineering
InstitutionsHarvard Medical School, Massachusetts Institute of Technology
Doctoral advisorJohn Davies & Molly Shoichet
Other academic advisorsRobert S. Langer

Jeff Karp is a Canadian–born biomedical engineer. He is a Professor of Medicine at Harvard Medical School, Brigham and Women’s Hospital, and the principal faculty at the Harvard Stem Cell Institute and Affiliate Faculty at the Massachusetts Institute of Technology through the Harvard–MIT Division of Health Sciences and Technology. He is also an affiliate faculty at the Broad Institute.



Karp was born and raised in Peterborough, Ontario.[1] He graduated from McGill University in 1999 with a degree in chemical engineering.[2] While at McGill he also co-founded the McGill Engineering Code of Ethics “The Blueprint”.[3]

He received a Ph.D. in Chemical and Biomedical Engineering from the University of Toronto in 2004.[2]

From 2004 until 2006, Karp was a postdoctoral fellow in Robert Langer‘s laboratory at MIT in the Harvard–MIT Program of Health Sciences and Technology;[4] Karp had applied for the position but Langer had no funds to pay him, so Karp secured funding from the Natural Sciences and Engineering Research Council and Langer accepted him.[5]


In the Langer lab, Karp was inspired by another lab’s publication in Nature that described adhesives based on the way that gecko‘s feet stick to surfaces; he and Langer applied for funding from NSF to make medical adhesives based on geckos, and received the funding.[5]

In 2007 he received an appointment and his own lab at Brigham and Women’s Hospital, at a location near MIT; he retained his association with the Harvard–MIT HST program.[6] He has made mentoring high school students, undergraduates, PhD students, and post docs a priority, and in 2008 he won the Outstanding Undergraduate Student Mentor Award at MIT,[7] and in 2010 he won the Thomas A. McMahon Mentoring Award from the HST program.[8]

In 2013 the company Gecko Biomedical was founded based on the gecko adhesive work, as well as subsequent work done in the Karp lab based on secretions of sandcastle worms.[6]

In 2014 the company Skintifique was formed to commercialize a barrier cream Karp had invented to prevent skin reactions in people with nickel allergy.[9]

In 2015 the company Frequency Therapeutics was founded to create treatments for hearing loss based on work done by Langer and Karp inspired by the ability of some amphibians and birds to regrow hair cells that have been damaged.[10]

In 2016 the company Alivio Therapeutics was founded based on work by Langer and Karp on a hydrogel to deliver drugs, intended to stick to tissue and only release the drug in response to inflammation.[11]


Technology Review listed him in 2008 as one of the top innovators under the age of 35 (TR35).[12] Karp received the 2011 Young Investigator award from the Society for Biomaterials,[13] and also in 2011, the Boston Business Journal profiled him as a Champion in Health Care Innovation.[14]



“Parasite inspires new research for Harvard scientist from Peterborough”. The Peterborough Examiner. 16 October 2013. Archived from the original on 3 March 2018. “Alumni”. Chemical Engineering. Retrieved 3 March 2018. “Reporter: The Blueprint”. McGill Reporter. 25 February 1999. “Karp Biosketch”. Harvard-MIT Division of Health Sciences and Technology. Archived from the original on 26 June 2009. Godfrey, Rena (24 July 2017). “The Bioinspirationalist: Dr. Jeffrey Karp looks to nature to solve big medical issues”. Rena Godfrey’s Lifestyles Magazine. Parker, Laura (25 October 2016). “Inspired by nature: the thrilling new science that could transform medicine”. The Guardian. “Prof. Jeff Karp and his gecko-inspired band-aid”. MIT Admissions. May 31, 2008. “Thomas A. McMahon Mentoring Award | Harvard-MIT Health Sciences and Technology”. Harvard-MIT HST Program. Retrieved 3 March 2018. Fischer, S (2014). “At the interface of disciplines: Jeffrey Karp pulls from nature and nano to transform medicine”. IEEE Pulse. 5 (2): 30–3. doi:10.1109/MPUL.2013.2296799. PMID24625588. “Frequency, Led by MIT’s Langer, Aims to Fight Hearing Loss With Drugs”. Xconomy. 5 January 2017. Adams, Ben (May 10, 2016). “Fresh from a new CAR-T biotech, PureTech launches Alivio Therapeutics”. FierceBiotech. “2008 Top 35 Innovators Under 35”. Technology Review. 2008. Retrieved August 14, 2011. “Press Release: Two from Brigham and Women’s Hospital Receive Society for Biomaterials Young Investigator Award”. Brigham and Women’s Hospital. 9 December 2010. Archived from the original on 24 June 2011.

  1. Lowe, Chelsea (August 26, 2011). “Champions in Health Care: Jeffrey Karp, innovator”. Boston Business Journal. Retrieved 30 May 2012.

External links

Authority controlNKC: mub20181006834


Navigation menu






Add links

Jeffrey Karp, 32

Gecko-inspired surgical tape

Harvard-MIT Division of Health Sciences and Technology

Bioengineer Jeffrey Karp may finally have found a noninvasive alternative to the sutures and staples that have long been a mainstay of surgery and emergency medicine. Using a biodegradable elastic polymer, Karp and his colleagues have created a surgical tape that is covered with nanoscale pillars akin to the gripping structures on geckos’ feet. Coated with a sugar-based glue, the tape securely closes a surgical incision and then degrades completely over time.

Karp can adapt the polymer to suit different applications: a patch for the heart, for example, would need to be more stretchable than one for the liver, while one to close cuts on the skin would need a different pattern of pillars. The polymer can also release drugs to help tissue heal. More than two dozen companies are interested in licensing the tape, which has shown promise in early animal tests. If all goes well, gecko tape could enter clinical trials within five years. —Katherine Bourzac



Imagem de fundo
Jeff Karp

Status: disponível

Jeff Karp 

 Conexão de 1º grau1º

Professor, Brigham and Women’s Hospital, Harvard Medical School

Boston, Massachusetts

Jeff works closely with a highly multidisciplinary group of leaders and emerging leaders to develop and rapidly advance translational platforms to improve patient care. A recent talk that he gave at TEDx Beacon Street details his lab’s problem solving strategy: His lab has no specific disease or technology focus, rather they focus broadly on medical problem solving. In Boston one must have at least 3 affiliations for people to take you seriously, he has 5 (in case he loses a couple)

He has published >125 peer-reviewed papers (>17,000 citations) & has given 300 national and international invited lectures & has >100 issued or pending patents. Karp has co-founded seven companies including: Gecko Biomedical, Skintifique, Frequency Therapeutics, Alivio Therapeutics, Molecular Infusions, Landsdowne Labs, and AltrixBio.

The Boston Business Journal recognized him as Champion in Healthcare Innovation & MIT’s Technology Review Magazine (TR35) recognized him as a top innovator in the world (3 members from his lab have received this award). Boston Magazine recently recognized Jeff as one of 11 Boston Doctors Making Medical Breakthroughs.

His work was selected by Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine.” He gave a TEDMED talk on bioinspired medical innovation & is a member of the TEDMED Editorial Advisory Board + was a commencement speaker at the University of Toronto.

He is frequently sought as an advisor on science/business to industry executives & scientists and has served as consultant or scientific advisory board member to dozens of biotech, pharma, & med device companies.

Karp was selected as the Outstanding Faculty Undergraduate Mentor among all MIT Faculty & he received the HST McMahon Mentoring award for being the top mentor of Harvard-MIT students. To date, 21 trainees from his lab have secured faculty positions & many others impactful positions in pharma & biotech industries.


  • Nome da empresaBrigham and Women’s Hospital, Harvard Medical SchoolDuração total11 anos 11 meses
    • TítuloProfessor of MedicinePeríodojan de 2018 – o momentoDuração do emprego1 ano 5 mesesLocalidadeGreater Boston Area
    • TítuloAssociate ProfessorPeríodojun de 2012 – jan de 2018Duração do emprego5 anos 8 mesesLocalidadeGreater Boston Area
    • TítuloCo-Director of Regenerative TherapeuticsPeríodojun de 2010 – 2013Duração do emprego3 anos
    • TítuloAssistant ProfessorPeríodojul de 2009 – jun de 2012Duração do emprego3 anosLocalidadeBoston
    • TítuloInstructor of MedicinePeríodojul de 2007 – jun de 2009Duração do emprego2 anosLocalidadeBoston

Editorial Advisory Board MemberNome da empresaTEDMEDPeríodo2015 – o momentoDuração do emprego4 anos

Honored to serve on the 2015,2016 and 2017 TEDMED Editorial Advisory Board for curating thestage program’s themes, topics, speakers and performers.Co-Founder, Scientific Advisory Board Member, and Board ObserverNome da empresaAlivio TherapeuticsPeríodomai de 2016 – o momentoDuração do emprego3 anos 1 mêsLocalidadeGrande Boston e Região, Estados UnidosAssociate MemberNome da empresaBroad InstitutePeríodoout de 2015 – o momentoDuração do emprego3 anos 8 mesesCo-Founder, Co-Chair of the Scientific Advisory BoardNome da empresaFrequency TherapeuticsPeríodonov de 2014 – o momentoDuração do emprego4 anos 7 mesesLocalidadeGrande Boston e Região, Estados Unidos

Frequency Therapeutics, is a biotechnology company at the forefront of translating groundbreaking discoveries in the area of cell programming, an approach recognized with the 2012 NobelPrize, to patients. Frequency has solved a key bottleneck in bringing stem cell programming topatients – namely by harnessing rapidly translatable small molecule combinations t… Visualizar maisExibir mais 5 experiências 

Formação acadêmica


Jeff tem 14 publicações14


  • Extracellular Vesicles Commercial Potential As Byproducts of Cell Manufacturing for Research and Therapeutic Use
  • A Small-Molecule Screen for Enhanced Homing of Systemically Infused Cells
  • Mesenchymal stem cells: immune evasive, not immune privileged
  • Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny
  • Prodrugs as self-assembled hydrogels: a new paradigm for biomaterials
  • Prodrugs as self-assembled hydrogels: a new paradigm for biomaterials
  • Microstructured barbs on the North American porcupine quill enable easy tissue penetration and difficult removal
  • Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease
  • Multipotent Stromal Cells Transmigrate Between and Directly Through TNF-a-activated Endothelial Cells
  • Tracking Mesenchymal Stem Cells with Iron Oxide Nanoparticle Loaded Poly(lactide-co-glycolide) Microparticles

Jeff tem 1 reconhecimento1

reconhecimento e/ou prêmio

  • 40 under 40

Jeffrey Karp, PhD

Brigham & Women’s Hospital
Harvard Medical School
Harvard-MIT Division of Health Sciences and Technology

Jeffrey Karp, PhD

Dr. Jeff Karp is a leading researcher in the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. He is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology (where he teaches to MIT-Sloan business school students). He has published >100 peer-reviewed papers (with >13,000 citations) and has given 250 national and international invited lectures and has >100 issued or pending patents. Several technologies developed in his lab have formed the foundation for multiple products on the market and currently under development and for the launch of four companies including Skintifique, Gecko Biomedical, Alivio Therapeutics, Frequency Therapeutics.

His laboratory has been funded by multiple companies, foundations and governmental funding agencies including the Bill and Melinda Gates Foundation, NFL, Johnson & Johnson, Phillips, Sanofi, UCB, NIH, DOD, US Army, Kenneth Rainin Foundation, Helmsley Trust, JDRF, Rheumatology Research Foundation, Coulter Foundation, Prostate Cancer Foundation, Brain Science Foundation, American Heart Association, Deshpande Foundation, Institute for Pediatric Innovation, Boston Children’s Hospital, Brigham and Women’s Hospital, the Government of India and the Government of Korea. Dr. Karp also won an internal Shark Tank award judged by Kevin O’Leary.

Karp’s work has been discussed in hundreds of newspapers, online websites, television newscasts, and radio shows around the world including CNN, ABC News, NBC, Boston Globe, LA Times, BBC, Discovery, National Geographic, The Atlantic, The Guardian, American Museum for Natural History, Popular Mechanics, CTV Canada AM. Karp has also appeared multiple times on CBC’s Quirks and Quarks and NPR Science Fridays.

The Boston Business Journal recognized him as a Champion in Healthcare Innovation and MIT’s Technology Review Magazine (TR35) also recognized Dr. Karp as being one of the top innovators in the world (3 members from his laboratory have subsequently received this award).

His work has been selected by Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine.” He gave a TEDMED talk at the Kennedy Center in DC on bioinspired medical innovation and since 2015 has been a member of the TEDMED Editorial Advisory Board (only member to be elected to the board 3 years in a row). In 2015 and 2016 he received Breakthrough Awards from the Kenneth Rainin Foundation and in 2015 was a commencement speaker in at the University of Toronto. He also serves as a consultant to the Kenneth Rainin Foundation and the Crohn’s and Colitis Foundation on the topic of new technologies for Inflammatory Bowel Disease. He has deep consulting expertise with startups and with several Fortune 500 companies across a wide spectrum of areas including drug delivery, medical devices, consumer healthcare products, and stem cell therapeutics.

Jeff was selected as the Outstanding Faculty Undergraduate Mentor among all Faculty at MIT and he received the HST McMahon Mentoring award for being the top mentor of Harvard-MIT students. To date, 18 trainees from his laboratory have secured faculty positions and several have transitioned into impactful careers in pharma, biotech, medtech, and venture capital.

Contact Information


Karp Laboratory


Brigham and Women’s HospitalHarvard Medical SchoolHarvard-MIT Division of Health Sciences and Technology

Research Interest(s)




HSCI Status

Principal Faculty

About Harvard Stem Cell Science

Advancing Biomedicine From Classroom to Clinic
The Harvard Stem Cell Institute and Harvard Department of Stem Cell and Regenerative Biology advance the understanding of human development and disease, support the discovery of stem cell-based therapies and cures for diseases, create collaborations across traditional institutional and disciplinary boundaries, and teach and train the next generation of leading stem cell scientists. Admin LoginOpenScholar Copyright © 2019 The President and Fellows of Harvard College | Accessibility | Report Copyright Infringement

Professor Dr. Jeroen J. Bax



Jeroen Bax MD PhD President of the European Society of Cardiology: He is a little more than halfway through his 2-year term as President of the European Society of Cardiology (ESC), but Jeroen Bax can already hear the clock ticking

Issue Section: CardioPulse


‘I knew my time in office would go by quickly,’ said Bax. ‘What surprised me most is the intensity of it all. There are so many issues everyday that only the president can resolve. And it requires constant balancing between long-term planning and short-term management.’

For this cardiovascular imaging professor from Leiden University Medical Center (LUMC) in the Netherlands, the solution is all about preparation. ‘If you prepare properly, if your objectives are clear and you organise carefully, you improve your odds for success. But I also realise that running such a large society like the ESC is like steering a huge cruise ship. You should make minimal course changes and probably no more than by 1 or 2 degrees. You need to work within the margins you have, and follow the direction set by your predecessors, in my case Fausto Pinto, Panos Vardas, and Michel Komajda.’

During his first year as ESC president, Bax oversaw the creation of a Working Group on Cardiovascular Regenerative and Reparative Medicine and a Council on Heart Valve Disease. He has launched both an Ethical Committee and an Industry Committee to grapple with increasingly complex issues inside and outside the Society.

‘We need to be fit for the future,’ said Bax. ‘We need to be ready for a rapidly changing environment so that we can anticipate and respond quickly to whatever comes our way.’

He has also fine-tuned the structure of existing ESC committees so that they operate more smoothly and is focused on instilling what he calls a ‘we feeling’ among members of the ESC board.

‘I am trying to impress on everyone that we are doing this together and that together we always need to feel responsible,’ he said. ‘No one is sitting on the board to defend a particular interest. We are here to work for the betterment of this unique Society.’

Bax, who was born and raised in Amsterdam, was the first member of his family to study medicine (Leiden, 1984–90). He later spent time at the University of Miami where he had his first exposure to research, working in immunology and basic science. His PhD thesis was in nuclear cardiology where he focused on detection of the hibernating myocardium (Amsterdam, 1992–96). He was hooked. ‘I realized the exciting possibilities of imaging to better understand disease and optimise treatment’.

By 2006, Bax was a professor of cardiology at Leiden, integrating the full range of imaging modalities including echocardiography, MRI, nuclear imaging, and CT imaging.

‘Although we had specialists in every modality, nobody crossed borders. We did,’ he said. It took 15 years to build his team, expanding the focus to research, then adding education and training.

Dr Eugene Braunwald described Bax this way: ‘Jeroen understands that academic physicians are like runners in a relay race. He drives constantly to assure that his successors will be superbly qualified to accept the baton from him and carry it the greatest distance along this noble track.’

By 2018, a total of 60 Fellows will have passed through the doors of Leiden’s Cardiac Imaging Research Center. Mentorship is an area of work that means much to Bax.


‘I care a lot about the new generation and giving them opportunities in the same way that I was given opportunities by generous teachers such as Shahbudin Rahimtoola, the US physician who discovered the concept of the “hibernating myocardium”. You meet people who help you, and you really appreciate that you have an obligation to pass it on to the next generation.’

One such protégé is Victoria Delgado, MD, who joined Bax’s team in 2007 as a Fellow from Spain, and never left. She says: ‘I was amazed by the facilities, and the organization, and how generous Prof Bax was with all of us. He is always ahead of his time. He encouraged us to follow new ideas and he created a very positive work environment. He takes everyone’s success seriously. He knows how to guide young Fellows and make sure they will enjoy their project.’

Bax is currently a Deputy Editor for the European Heart Journal and a proud contributor to UpToDate, an online, evidence-based learning platform. He is also one of the few Europeans closely involved with the Journal of the American College of Cardiology, where he worked for 7 years as associate editor.

Bax’s involvement with the ESC now spans 2 decades and encompasses all the roles and functions of the Society, including working groups, committees, editing, authorship, education, guidelines, and his current role as president. He credits William Wijns, FESC,—his PhD thesis external referee and now a professor in the Republic of Ireland—with introducing him to the ESC in the mid-1990s. Later, Kim Fox, FESC, invited him to chair the ESC’s Scientific Programme Committee at the young age of 40. He enjoyed the challenge and found a flair for re-organizing things to make them run more efficiently. He says: ‘Before Kim Fox’s presidency there were about 100 or so people all trying to build the sessions, so we changed it into nine big ‘topic blocks’ representing all clinical areas of cardiology with coordinators who developed sessions with their groups and then came together to present what they had agreed. It was again the “we feeling,” a winning formula which resulted in great sessions, produced much more efficiently with everyone working together.’

Elected last year at just 50 years of age, he is the youngest president in the Society’s history. He is determined to accomplish as much as he can before ESC Congress next August when his tenure comes to an end. High on his agenda is introducing the new ESC Textbook of Cardiovascular Medicine, third edition and the corresponding online version which should be available in the spring. This is the first major update since 2009 and he wants to integrate it seamless into ESC’s vast educational portfolio.

‘We are also investing heavily in digital health,’ he says. ‘We created a digital health village at ESC Congress in Barcelona and we have an ESC task force working to create an array of new opportunities for cardiologists in this area. We have so much we want to accomplish in the coming months, and on so many different fronts. Time is running short.’

Conflict of interest: none declared. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email:




John McKenzieEuropean Heart Journal, Volume 39, Issue 6, 07 February 2018, Pages 425–426, Published: 06 February 2018

Strategic Partner

´´Prof.dr. Jeroen J. Bax, FESC (Leiden, Netherlands)   ESC Immediate Past-President (2018 – 2020), Jeroen Bax is Director of non-invasive imaging and Director of the echo-lab at the Leiden University Medical Center. His main interests include clinical cardiology, heart failure, cardiac resynchronization therapy and the application of all different imaging modalities to these clinical fields.   Professor Bax has authored numerous papers and holds several positions in national and international scientific organizations, as well as serving on the editorial boards of many different journals. ´´


Jeroen Bax

Imaging / Echography physician Leiden University Medical Center – Leiden, Netherlands

Prof. Jeroen Bax is Director of Non-invasive Imaging and Director of the Echo Laboratory in the Department of Cardiology at the Leiden University Medical Center, The Netherlands. He is President of the European Society of Cardiology (ESC) and has lead the ESC Congress Program Committee. Professor Bax serves on the Editorial Boards of various journals including as Associate Editor for the Journal of the American College of Cardiology and Heart.

Job title Director Organization Echo Laboratory in the Department of Cardiology at the Leiden University Medical Center, The Netherlands

Jeroen Bax is Director of Non-invasive Imaging and Director of the Echo Laboratory in the Department of Cardiology at the Leiden University Medical Center, The Netherlands. He was President of the European Society of Cardiology (ESC) Congress Program Committee for 2007–2008. Professor Bax also serves on the Editorial Doards of various journals including as Associate Editor for the Journal of the American College of Cardiology and Heart.


Immediate Past President European Society Cardiology

Amsterdam, North Holland Province, Netherlands


Formação acadêmica

Jeroen Bax

Professor Cardiology, in particular imaging Name Prof.dr. J.J. Bax Telephone +31 71 526 1757 E-mail

Imaging in clinical cardiology

´´My main interest of research is related to imaging in clinical cardiology. In particular, the integration of the different imaging techniques (nuclear cardiology, echocardiography, multi-slice computed tomography and magnetic resonance imaging) into clinical issues.´´

The title of his inaugural lecture was ‘Cardiale beeldvorming – reis door de tijd

Professor Cardiology, in particular imaging

  • Faculteit Geneeskunde
  • Divisie 2
  • Hartziekten

Work address

LUMC Main Building
Albinusdreef 2
2333 ZA Leiden
Room number C5-P


  • European Heart Journal Associated Editor
  • European Society for Cardiology President
  • Lantheus Scientific Advisory Board



Jeroen J. Bax

Dr. Jeroen J. Bax
President of ESC
Leiden University Medical Center, The Netherlands

Dr. Jeroen J. Bax is Professor of Cardiology and Director of Non-Invasive Cardiac Imaging at the Department of Cardiology, Leiden University Medical Center, The Netherlands.

He has been working intensively with the European Society of Cardiology (ESC) and is currently serving as President of the organization.

Professor Bax has been Associate Editor of the American College Cardiology, and is currently Associate Editor of the European Heart Journal.

He has co-authored numerous scientific articles, has guided many PhD fellows and his main interests of research include imaging in heart failure, stable coronary artery disease, valvular heart disease and atrial fibrillation.

Professor Dr. Domingo Marcolino Braile

Currículo – Curriculum Lattes:

Braile Cardio – Cardiologista em São José do Rio Preto – SP

Domingo Marcolino Braile é Professor Titular Livre Docente em Cirurgia Cardíaca e Pró-Reitor da Faculdade de Medicina de São José do Rio Preto, Pesquisador do Conselho Nacional de Desenvolvimento Científico e Tecnológico e Professor Orientador da Faculdade de Medicina de São José do Rio Preto e da Faculdade de Medicina da Universidade Estadual de Campinas. Participou de mais de 200 bancas examinadoras de Mestrado, Doutorado, Livre Docência e Concursos Públicos, orientou mais de 40 dissertações e teses. Em toda sua carreira, em eventos científicos, proferiu mais de 900 conferências, apresentou mais de 700 trabalhos (autoria e co-autoria) e recebeu mais de 20 prêmios. Ocupa o cargo de Editor Chefe da Revista da Sociedade Brasileira de Cirurgia Cardiovascular (RBCCV), tornando a revista a única publicação internacional do gênero no hemisfério sul, além de incluir México e Caribe com a indexação da mesma no Medline/Pubmed e inclusão da mesma na base de dados ISI Web of Knowledge. Também criou as homepages da Sociedade Brasileira de Cirurgia Cardiovascular e da RBCCV, implantando a submissão e avaliação dos manuscritos eletronicamente. É membro de 19 Conselhos Editoriais. Publicou 19 capítulos, editou dois livros, tem mais de 350 artigos publicados em periódicos especializados e é colunista de dois jornais de São José do Rio Preto, com mais de 500 artigos publicados. Em 2009 foi condecorado com a mais elevada Honraria do Estado de São Paulo: a Ordem do Ipiranga, reservada aos cidadãos brasileiros e estrangeiros que prestaram serviços notórios aos paulistas. É Membro da Academia Rio-pretense de Letras e Cultura, assumindo a cadeira de número 11. Em 2013 ocupou a cadeira nº 48 da Academia de Medicina de São Paulo e em 2014 tornou-se Membro Honorário da Academia Nacional de Medicina (RJ). Em 2013 recebeu o 1º lugar do Prêmio Nacional de Inovação Tecnológica, promovido pela FINEP.

Informações coletadas do Lattes em 09/04/2019

Professor Dr. Denis Nobel

Emeritus Professor of Cardiovascular Physiology

´´Denis Noble CBE FRS FMedSci (born 16 November 1936) is a British biologist who held the Burdon Sanderson Chair of Cardiovascular Physiology at the University of Oxford from 1984 to 2004 and was appointed Professor Emeritus and co-Director of Computational Physiology. He is one of the pioneers of Systems Biology and developed the first viable mathematical model of the working heart in 1960.[4][5][6][7][8] ´´

´´Denis Noble (16 de Novembro de 1936) é um biólogo britânico que, tendo regido a cadeira Burdon Sanderson de Fisiologia Cardiovascular na Universidade de Oxford (1984-2004), é actualmente Professor Emérito e co-Director do Departamento de Fisiologia Computacional da mesma Universidade.[1] ´´

´´Denis Noble é um dos pioneiros da Biologia Sistémica, tendo desenvolvido em 1960 o primeiro modelo matemático viável da função cardíaca. Nos mecanismos dos batimentos cardíacos ficou claro que não havia apenas só um oscilador, mas um laço de retroalimentação entre vários canais. Usou modelos de computador de órgãos e sistemas de órgãos para interpretar a função molecular ao nível de todo o organismo. A sua equipa utilizou supercomputadores para a criação de um coração virtual. Como Secretário Geral da União de Ciências Fisiológicas, de 1993 a 2001, contribuiu para difundir a nível internacional o uso de modelos computorizados para simular quantitativamente funções da fisiologia, nomeadamente ao nível do genoma.[2] ´´


Noble was educated at Emanuel School and University College London (UCL).[1][4] In 1958 he began his investigations into the mechanisms of heartbeat. This led to two seminal papers in Nature in 1960[9][10] giving the first proper simulation of the heart. From this work it became clear that there was not a single oscillator which controlled heartbeat, but rather this was an emergent property of the feedback loops in the various channels. In 1961 he obtained his PhD working under the supervision of Otto Hutter at UCL.[11][12]


Noble’s research focuses on using computer models of biological organs and organ systems to interpret function from the molecular level to the whole organism. Together with international collaborators, his team has used supercomputers to create the first virtual organ, the virtual heart.[13][14]

As secretary-general of the International Union of Physiological Sciences 1993–2001, he played a major role in launching the Physiome Project, an international project to use computer simulations to create the quantitative physiological models necessary to interpret the genome, and he was elected president of the IUPS at its world congress in Kyoto in 2009.[15]

Noble is also a philosopher of biology, and his books The Music of Life and Dance to the Tune of Life challenge the foundations of current biological sciences, question the central dogma, its unidirectional view of information flow, and its imposition of a bottom-up methodology for research in the life sciences[16]


His 2006 book The Music of Life examines some of the basic aspects of systems biology, and is critical of the ideas of genetic determinism and genetic reductionism. He points out that there are many examples of feedback loops and “downward causation” in biology, and that it is not reasonable to privilege one level of understanding over all others. He also explains that genes in fact work in groups and systems, so that the genome is more like a set of organ pipes than a “blueprint for life”. His 2016 book Dance to the Tune of Life sets these ideas out in a broad sweep from the general principle of relativity applied to biology, through to the role of purpose in evolution and to the relativity of epistemology.

He contrasts Dawkins‘s famous statement in The Selfish Gene (“Now they [genes] swarm … safe inside gigantic lumbering robots … they created us, body and mind; and their preservation is the ultimate rationale for our existence”) with an alternative view: “Now they


are trapped in huge colonies, locked inside highly intelligent beings, moulded by the outside world, communicating with it by complex processes, through which, blindly, as if by magic, function emerges. They are in you and me; we are the system that allows their code to be read; and their preservation is totally dependent on the joy we experience in reproducing ourselves. We are the ultimate rationale for their existence”. He then suggests that there is no empirical difference between these statements, and says that they differ in “metaphor” and “sociological or polemical viewpoint”.[17]

He argues that “the paradigms for genetic causality in biological systems are seriously confused” and that “The metaphors that served us well during the molecular biological phase of recent decades have limited or even misleading impacts in the multilevel world of systems biology. New paradigms are needed if we are to succeed in unravelling multifactorial genetic causation at higher levels of physiological function and so to explain the phenomena that genetics was originally about.”[18]


Noble has called for an extended evolutionary synthesis, and more controversially a replacement for the modern synthesis.[19][20]

He has argued that from research in epigenetics, acquired characteristics can be inherited and in contrast to the modern synthesis, genetic change is “far from random” and not always gradual. He has also claimed that the central dogma of molecular biology has been broken as an “embodiment of the Weismann Barrier”(Article in the journal PHYSIOLOGY), and a new synthesis will integrate research from physiology with evolutionary biology.[21][22][23]

Principles of Systems Biology

Denis Noble at a meeting on Systems Biology at Chicheley Hall, August 2013

Noble has proposed Ten Principles of Systems Biology:[24][25]

  1. Biological functionality is multi-level
  2. Transmission of information is not one way
  3. DNA is not the sole transmitter of inheritance
  4. The theory of biological relativity: there is no privileged level of causality
  5. Gene ontology will fail without higher-level insight
  6. There is no genetic program
  7. There are no programs at any other level
  8. There are no programs in the brain
  9. The self is not an object
  10. There are many more to be discovered; a genuine ‘theory of biology’ does not yet exist


  • 1961–1963 – Assistant lecturer in Physiology, University College London
  • 1961–1963 – Vice-warden of Connaught Hall] (University of London)[26]
  • 1963–1984 – Fellow and tutor, Balliol College, Oxford. University Lecturer in Physiology
  • From 1967 – Editor of Progress in Biophysics and Molecular Biology[27]
  • 1969–1970 – Visiting professor and visiting scientist of the Canadian MRC
  • 1971–1989 – Head (praefectus) of the Balliol College Graduate Centre at Holywell Manor
  • 1975–1985 – Leader of MRC Programme Grant team
  • 1983–1985 – Vice-master of Balliol College
  • 1986 – co-founder of Save British Science, now the Campaign for Science and Engineering
  • 1984–2004 – Burdon Sanderson Professor of Cardiovascular Physiology, Oxford University
  • 1984–2004 – Professorial fellow, Balliol College
  • From 2004 – Emeritus professor of Cardiovascular Physiology, Oxford University
  • From 2004 – Emeritus fellow of Balliol College, Oxford
  • From 2004 – Director of Computational Physiology, Oxford
  • 2003–2007 – Adjunct professor, Xi’an Jiaotong University, Shaanxi province, China
  • From 2005 – Visiting professor, Osaka University, Japan
  • 2009–2017 – President, International Union of Physiological Sciences [28]
  • From 2009 – Co-founder and editor of Voices from Oxford[29]
  • 2011–2017 – Editor in chief of Interface Focus[30][31][32]
  • From 2014 – Member and co-founder of The Third Way Of Evolution[33]


Noble has published over 600 articles in academic journals,[3][14] including Nature,[9][10][34][35][36][37] Science,[38][39] PNAS,[40] Journal of Physiology,[41][42][43][44][45] Progress in Biophysics & Molecular Biology;[46] Many articles in national press. He is the author or editor of 11 books, including:

Awards and honours

´´His major invited lectures include the Darwin Lecture for the British Association in 1966,[47] the Nahum Lecture at Yale in 1977 and the Ueda lecture at Tokyo University in 1985 and 1990. He was President of the Medical Section of the British Science Association 1991–92.´´

´´In 1979 he was elected a Fellow of the Royal Society. His nomination for the Royal Society reads:´´

´´Distinguished for the discovery of slowly activated potassium currents in the heart and a quantitative analysis of their role in controlling repolarization and pacemaker activity; the discovery of the ionic mechanisms by which adrenaline increases heart rate. He has shown that therapeutic levels of cardiac glycosides may increase, rather than decrease, potassium gradients in the heart, and has published an analytical treatment of membrane excitation theory and cable theory that provides a modern basis for the concepts of safety factor, liminal length, excitation time constants and the phenomenon of repetitive firing.[2]´´

´´He was elected an Honorary Member of the Royal College of Physicians in 1988 and an Honorary Fellow in 1994, an Honorary Member of the American Physiological Society in 1996 and of the Physiological Society of Japan in 1998. In 1989 he was elected a Member of the Academia Europaea. In 1998, he also became a founding Fellow of the Academy of Medical Sciences.[48] In 1998 he was awarded a CBE.[49] ´´

´´He has honorary doctorates from the University of Sheffield (2004),[50] the Université de Bordeaux (2005) and the University of Warwick (2008).[51] ´´

´´He was awarded the Pierre Rijlant Prize (1991), Baly Medal Royal College of Physicians (1993), Pavlov Medal Russian Academy of Sciences (2004), Mackenzie Prize (2005), Medal of Merit (2008)[52] and the British Heart Foundation Gold Medal (1985).´´

´´He is an Honorary Foreign Member of the Académie Royale de Médecine de Belgique (1993),[53] of the Istituto Lombardo Accademia di Scienze e Lettere, and received the Pavlov Medal of the Russian Academy of Sciences (2004). ´´

Professor Dr. James D. Griffin

  • Professor, Medicine, Harvard Medical School
  • Chair, Medical Oncology, Dana-Farber Cancer Institute
  • Director, Medical Oncology, Brigham And Women’s Hospital

Dana-Farber Cancer Institute
Phone: (617) 632-3360
Fax: (617) 632-2260

AddressDana-Farber Cancer Institute
Mayer 540
44 Binney St
Boston MA 02115


493Research items




Professor of Medicine – Harvard Medical School – Período1996 – o momento Duração do emprego: 23 anos – Localidade Boston, MA – physician – Dana-Farber Cancer Institute – Período jul de 1977 – o momento – Duração do emprego: 41 anos 11 meses

Formação acadêmica

Licenças e certificados

About James D. Griffin, MD



Leadership Title

Chief, Division of Medical Oncology


Cancer – Medical Oncology

Medical Oncology

Clinical Interests

acute myeloid leukemia (AML)

chronic myeloid leukemia (CML)




Medical School

Harvard Medical School/ BWH, 1974


Johns Hopkins Hospital, 1974 – 1976

Board Certifications

Internal Medicine, 1977 Hematology, 1978 Medical Oncology, 1981


Massachusetts General Hospital, 1976 – 1977 Dana-Farber Cancer Institute, 1977 – 1979

Dana-Farber Cancer Institute, 1979 – 1980

Professora Dra. Eliane Carneiro Gomes

Currículo – Curriculum Lattes:

Possui graduação em Farmácia e Bioquímica, mestrado em Físico-química ambos pela Universidade Federal de Santa Catarina (UFSC) e doutorado em Agronomia (Produção Vegetal) pela Universidade Federal do Paraná (UFPR) (2003). Atualmente é professora associada aposentada da UFPR onde atuava junto aos cursos de Farmácia, Medicina, Residência Multiprofissional em Saúde da Família e Programas de Pós graduação em Ciências Farmacêuticas (Ainda ativa) e em Saúde Coletiva. Pesquisa na área de Saúde Coletiva, atuando principalmente nos seguintes temas: saúde e meio ambiente, agentes biológicos e saúde, plantas medicinais, fitoterapia, vigilância em saúde e educação em saúde. É membro titular pela UFPR da comissão multidisciplinar da Secretaria Estadual Saúde do Paraná que elaborou decreto sobre Resíduos de Serviços de Saúde. É líder do grupo de pesquisa do diretório CNPq: “Vigilância em Saúde e Promoção da Saúde”. Foi coordenadora administrativa e tutora do PET-Saúde ediçoes 2010-2012 e 2013-1015, desenvolvendo ações que integravam o ensino,serviço e comunidade. Coordenou por 13 anos projeto pedagógico de cunho social – UFPR/Secretaria Municipal de Saúde de Curitiba e comunidades locais. Codirector de TRT- Maestría en Salud Publica/Salud Comunitaria em 2015-Universidad Autónoma de Nayarit, México. Ministrou disciplina junto à Assessoria de Relações Internacionais em 2016 para aluno intercambista da Universität München, Alemanha.

Informações coletadas do Lattes em 05/04/2019



  1. Doxycycline Tab Internet Pharmacy [url=]buy cialis online united states[/url] Canadian Pharmacy Quick Shipping Cialis accutane online canada no prescription


  2. Wow that was strange. I just wrote an extremely long comment but after I clicked submit my comment didn’t appear. Grrrr… well I’m not writing all that over again. Anyway, just wanted to say excellent blog!


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s